Jazz Pharmaceuticals (NasdaqGS:JAZZ) FY Conference Transcript

Jazz Pharmaceuticals FY Conference Summary Company Overview - Company: Jazz Pharmaceuticals (NasdaqGS:JAZZ) - Event: FY Conference on March 03, 2026 - Key Speakers: CFO Philip Johnson, Head of Oncology Clinical Development Amal Melhem-Bertrandt, Head of Investor Relations John Bluth Key Points Financial Performance - 2025 Achievements: - Record revenue with the highest revenue quarter in Q4 - 21st consecutive year of revenue growth - Revenue growth: 12% in Xywav, 9% in Epidiolex, and strong start for Modeyso - Oxybate franchise surpassed $2 billion, Epidiolex exceeded $1 billion, and oncology franchise also above $1 billion [4][5] - 2026 Revenue Guidance: - Expected total revenue between $4.25 billion and $4.5 billion, representing a 2.5% growth at the midpoint - Anticipation of 22nd consecutive year of revenue growth, driven by double-digit growth in epilepsy and oncology portfolio [7][8] Pipeline Developments - Zanidatamab: - Completed filing for sBLA for GEA, with a focus on first-line maintenance use in small cell lung cancers [10][11] - Data showed over 2 years of overall survival, indicating potential for practice-changing results [4][31] - Epidiolex: - ANDA settlements provide visibility to exclusivity into the late 2030s, with ongoing efforts to expand brand presence [25][26] - Modeyso: - Strong early launch performance, exceeding expectations, with peak sales potential estimated over $500 million in the U.S. [45][46] Corporate Development - Acquisition of Chimerix: - Enhanced oncology portfolio with Modeyso and significant financial assets, including a deferred tax asset reducing future cash taxes by over $200 million [5][6] - Future Transactions: - Plans for one or more transactions in 2026, focusing on epilepsy, oncology, and rare diseases [12][50] Market Dynamics - Xywav and Generics: - Agreement with Hikma allows authorized generic to remain until the end of 2029, with two generics already in the market [16][17] - Unique low sodium benefit of Xywav is expected to maintain its market share despite generics [17][18] - Idiopathic Hypersomnia (IH): - Over 5,000 patients on Xywav for IH, with potential for growth as awareness increases [19][20] Strategic Focus - CEO Transition: - Successful transition from Bruce Cozadd to Renee Gala, with a refined strategy focusing on rare diseases [7] - Expansion Opportunities: - Interest in expanding zanidatamab into breast cancer and other indications, with ongoing studies showing promising results [41][44] Conclusion - Jazz Pharmaceuticals is positioned for continued growth in 2026, with a strong financial outlook, promising pipeline developments, and strategic corporate initiatives aimed at enhancing its market presence in rare diseases and oncology [13][50]